BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16505950)

  • 1. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies.
    Schwartsmann G; DiLeone LP; Horowitz M; Schunemann D; Cancella A; Pereira AS; Richter M; Souza F; da Rocha AB; Souza FH; Pohlmann P; De Nucci G
    Invest New Drugs; 2006 Sep; 24(5):403-12. PubMed ID: 16505950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
    Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
    Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
    Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
    Koppán M; Halmos G; Arencibia JM; Lamharzi N; Schally AV
    Cancer; 1998 Oct; 83(7):1335-43. PubMed ID: 9762934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
    Rick FG; Buchholz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Aigner E; Perez R; Seitz S; Block NL; Hohla F
    Cell Cycle; 2012 Jul; 11(13):2518-25. PubMed ID: 22751419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration.
    Pinski J; Yano T; Rekasi Z; Cai RZ; Radulovic S; Schally AV
    Regul Pept; 1992 Oct; 41(3):185-93. PubMed ID: 1438988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Groot K; Halmos G
    Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
    Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
    J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G; Schally AV
    Proc Natl Acad Sci U S A; 1997 Feb; 94(3):956-60. PubMed ID: 9023364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K
    Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
    Radulovic S; Schally AV; Reile H; Halmos G; Szepeshazi K; Groot K; Milovanovic S; Miller G; Yano T
    Acta Oncol; 1994; 33(6):693-701. PubMed ID: 7946450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats.
    Pinski J; Yano T; Groot K; Cai RZ; Radulovic S; Schally AV
    Am J Physiol; 1992 Oct; 263(4 Pt 1):E712-7. PubMed ID: 1415689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
    Hohla F; Schally AV; Kanashiro CA; Buchholz S; Baker B; Kannadka C; Moder A; Aigner E; Datz C; Halmos G
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18671-6. PubMed ID: 18003891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
    Shirahige Y; Cai RZ; Szepeshazi K; Halmos G; Pinski J; Groot K; Schally AV
    Biomed Pharmacother; 1994; 48(10):465-72. PubMed ID: 7858155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
    Kiaris H; Schally AV; Sun B; Armatis P; Groot K
    Oncogene; 1999 Nov; 18(50):7168-73. PubMed ID: 10597318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.